Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 338 Records) |
| Query Trace: Disease Progression and EGFR[original query] |
|---|
| Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2022 Sep 25 (9): 651-657. Zhang Guowei, Cheng Ruirui, Niu Yuanyuan, Wang Huijuan, Yan Xiangtao, Zhang Mina, Zhang Xiaojuan, Yang Jinpo, Wei Chunhua, Ma Zhiyo |
| Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma. Frontiers in oncology 2022 12 985284. Jiang Meilin, Yang Pei, Li Jing, Peng Wenying, Pu Xingxiang, Chen Bolin, Li Jia, Wang Jingyi, Wu L |
| Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer. Cancer research and treatment 2022 Aug . Lee Jang Ho, Kim Eun Young, Park Cheol-Kyu, Lee Shin Yup, Lee Min Ki, Yoon Seong-Hoon, Lee Jeong Eun, Lee Sang Hoon, Kim Seung Joon, Lee Sung Yong, Lim Jun Hyeok, Jang Tae-Won, Jang Seung Hun, Lee Kye Young, Lee Seung Hyeun, Yang Sei Hoon, Park Dong Won, Park Chan Kwon, Kang Hye Seon, Yeo Chang Dong, Choi Chang-Min, Lee Jae Che |
| A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC. JTO clinical and research reports 2022 11 3 (12): 100416. Lai Gillianne G Y, Yeo Jia Chi, Jain Amit, Zhou Siqin, Pang Mengyuan, Alvarez Jacob J S, Sim Ngak Leng, Tan Aaron C, Suteja Lisda, Lim Tze Wei, Guo Yu Amanda, Shen Meixin, Saw Stephanie P L, Rohatgi Neha, Yeong Joe P S, Takano Angela, Lim Kiat Hon, Gogna Apoorva, Too Chow Wei, Da Zhuang Kun, Tan Wan Ling, Kanesvaran Ravindran, Ng Quan Sing, Ang Mei Kim, Rajasekaran Tanujaa, Wang Lanying, Toh Chee Keong, Lim Wan-Teck, Tam Wai Leong, Tan Sze Huey, Skanderup Anders M J, Tan Eng-Huat, Tan Daniel S |
Identifying Genetic Variants and Metabolites Associated with Rapid Estimated Glomerular Filtration Rate Decline in Korea Based on Genome-Metabolomic Integrative Analysis.
Metabolites 2022 11 12 (11): . Lee Sangjun, Han Miyeun, Moon Sungji, Kim Kyungsik, An Woo Ju, Ryu Hyunjin, Oh Kook-Hwan, Park Sue |
| The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study. Cancer medicine 2022 11 . Yu Xiaoqing, Si Jinfei, Wei Jingwen, Wang Yanling, Sun Yan, Jin Jianan, Zhang Xiaoyan, Ma Tonghui, Song Zheng |
| Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study. BMC cancer 2022 10 22 (1): 1035. Fujii Hiroaki, Nagakura Hideyuki, Kobayashi Nobuaki, Kubo Sousuke, Tanaka Katsushi, Watanabe Keisuke, Horita Nobuyuki, Hara Yu, Nishikawa Masanori, Miura Kenji, Koizumi Harumi, Ito Yu, Tsubakihara Motofumi, Miyazawa Naoki, Kudo Makoto, Shinkai Masaharu, Kaneko Takes |
| Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib. BMC cancer 2023 9 23 (1): 834. Kensuke Kanaoka, Hiromitsu Sumikawa, Shunsuke Oyamada, Akihiro Tamiya, Yuji Inagaki, Yoshihiko Taniguchi, Keiko Nakao, Yoshinobu Matsuda, Kyoichi Okish |
| The efficacy and safety of chemo-free therapy in epidermal growth factor receptor tyrosine kinase inhibitor-resistant advanced non-small cell lung cancer: A single-arm, phase II study. Cancer medicine 2023 9 . Shuyang Zhang, Lu Yang, Yaning Yang, Guangjian Yang, Haiyan Xu, Xueliang Niu, Yan Wa |
| Nivolumab as maintenance therapy following platinum-based chemotherapy in EGFR-mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial. Thoracic cancer 2023 9 . Jiwon Kim, Chang-Min Choi, Wonjun Ji, Jae Cheol L |
| First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study. Annals of medicine 2023 8 55 (2): 2243967. Yahua Wu, Bin Du, Chengliu Lv, Xiaohui Ji, Yanqin Lan, Na Yao, Yingjiao Zhu, Jinhuo L |
| Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial. Journal of cancer research and clinical oncology 2023 7 . Aidong Qu, Shiying Zhang, Hongxia Zou, Sixiu Li, Dandan Chen, Yaowen Zhang, Songsong Li, Huijun Zhang, Ji Yang, Yunkai Yang, Yubao Huang, Xiuling Li, Yuntao Zha |
| Selpercatinib monotherapy in a Chinese patient with RET fusion/EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report. Anti-cancer drugs 2023 6 . Lin Wu, Ying Cheng, Dingzhi Huang, Yuping Sun, Chengzhi Zhou, Jianying Zhou, Ye Guo, Jingxin Shao, Wanli Zhang, Shun |
| Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. The Lancet. Respiratory medicine 2023 5 . Shun Lu, Jianying Zhou, Hong Jian, Lin Wu, Ying Cheng, Yun Fan, Jian Fang, Gongyan Chen, Zhihong Zhang, Dongqing Lv, Liyan Jiang, Rong Wu, Xiangming Jin, Xiaodong Zhang, Junhong Zhang, Conghua Xie, Gengyun Sun, Dongning Huang, Jiuwei Cui, Renhua Guo, Zhigang Han, Zhendong Chen, Jin Liang, Wu Zhuang, Xingsheng Hu, Aimin Zang, Yi Zhang, Shundong Cang, Yuanbo Lan, Xi Chen, Laiyu Liu, Xingya Li, Jun Chen, Rui Ma, Yanzhen Guo, Ping Sun, Panwen Tian, Yueyin Pan, Zhe Liu, Peiguo Cao, Lieming Ding, Yang Wang, Xiaobin Yuan, Pengxiang |
| Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant ( L833V / H835L ) lung adenocarcinoma patient : a case report. Anti-cancer drugs 2023 5 . Zhilin Luo, Chengwen Luo, Runquan Zhou, Yajie Xiao, Tianhu Wa |
| Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA oncology 2023 5 . Stefania Napolitano, Vincenzo De Falco, Giulia Martini, Davide Ciardiello, Erika Martinelli, Carminia Maria Della Corte, Lucia Esposito, Vincenzo Famiglietti, Alessandra Di Liello, Antonio Avallone, Claudia Cardone, Alfonso De Stefano, Vincenzo Montesarchio, Maria Giulia Zampino, Roberto Bordonaro, Mario Scartozzi, Daniele Santini, Massimo Di Maio, Ferdinando De Vita, Lucia Altucci, Francesca Marrone, Fortunato Ciardiello, Teresa Troia |
| Chemotherapy outcomes in EGFR-TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study. Thoracic cancer 2023 5 . Chien-Yu Lin, Chia-Hao Hu, Chia-Fu Hsu, Jeng-Shiuan Tsai, Chian-Wei Chen, Chia-Yin Lin, Chao-Chun Chang, Yi-Ting Yen, Yau-Lin Tseng, Po-Lan Su, Chien-Chung L |
| Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. EClinicalMedicine 2023 5 59 101955. G D Marijn Veerman, Rene J Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J van der Wekken, Idris Bahce, Lizza E L Hendriks, Sander Croes, Christi M J Steendam, Evert de Jonge, Stijn L W Koolen, Neeltje Steeghs, Ron H N van Schaik, Egbert F Smit, Anne-Marie C Dingemans, Alwin D R Huitema, Ron H J Mathijss |
| Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations. Thoracic cancer 2023 4 . Zhang Ling, You Yunhong, Liu Xueli, Liu Fengjuan, Nie Keke, Ji Youx |
| Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report. Frontiers in oncology 2023 4 13 1151178. Xiaoting Ma, Xiu Liu, Kai Ou, Manman Zhang, Lizhen Gao, Lin Ya |
| Should We Perform Repeated Re-Biopsy for the Detection of T790M Mutation? Cancer research and treatment 2023 4 . Saerom Kim, Soo Han Kim, Jinmi Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop E |
| Genomic landscape and survival analysis of ctDNA "neo-RAS wild-type" patients with originally RAS mutant metastatic colorectal cancer. Frontiers in oncology 2023 4 13 1160673. Nicolazzo Chiara, Magri Valentina, Marino Luca, Belardinilli Francesca, Di Nicolantonio Federica, De Renzi Gianluigi, Caponnetto Salvatore, De Meo Michela, Giannini Giuseppe, Santini Daniele, Cortesi Enrico, Gazzaniga Pao |
| Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 2023 2 14 (1): 1071. Chmielecki Juliann, Mok Tony, Wu Yi-Long, Han Ji-Youn, Ahn Myung-Ju, Ramalingam Suresh S, John Thomas, Okamoto Isamu, Yang James Chih-Hsin, Shepherd Frances A, Bulusu Krishna C, Laus Gianluca, Collins Barbara, Barrett J Carl, Hartmaier Ryan J, Papadimitrakopoulou Vassili |
| Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature communications 2023 2 14 (1): 1070. Chmielecki Juliann, Gray Jhanelle E, Cheng Ying, Ohe Yuichiro, Imamura Fumio, Cho Byoung Chul, Lin Meng-Chih, Majem Margarita, Shah Riyaz, Rukazenkov Yuri, Todd Alexander, Markovets Aleksandra, Barrett J Carl, Hartmaier Ryan J, Ramalingam Suresh |
| Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. European journal of cancer (Oxford, England : 1990) 2023 2 183 38-48. Bylicki Olivier, Tomasini Pascale, Radj Gervais, Guisier Florian, Monnet Isabelle, Ricordel Charles, Bigay-Game Laurence, Geier Margaux, Chouaid Christos, Daniel Catherine, Swalduz Aurelie, Toffart Anne-Claire, Doubre Helene, Peloni Jean-Michel, Moreau Diane, Subtil Fabien, Grellard Jean-Michel, Castera Marie, Clarisse Benedicte, Martins-Lavinas Pedro-Henrique, Decroisette Chantal, Greillier Laurent, |
| Rapid Progression of Focal Segmental Glomerulosclerosis in Patients with High-Risk APOL1 Genotypes. Clinical journal of the American Society of Nephrology : CJASN 2023 2 18 (3): 344-355. Kallash Mahmoud, Wang Yujie, Smith Abigail, Trachtman Howard, Gbadegesin Rasheed, Nester Carla, Canetta Pietro, Wang Chen, Hunley Tracy E, Sperati C John, Selewski David, Ayoub Isabelle, Srivastava Tarak, Mottl Amy K, Kopp Jeffrey, Gillespie Brenda, Robinson Bruce, Chen Dhruti, Steinke Julia, Twombley Katherine, Reidy Kimberly, Mucha Krzysztof, Greenbaum Larry A, Blazius Brooke, Helmuth Margaret, Yonatan Peleg, Parekh Rulan S, Hogan Susan, Royal Virginie, D'Agati Vivette, Chishti Aftab, Falk Ronald, Gharavi Ali, Holzman Lawrence, Klein Jon, Smoyer William, Kretzler Matthias, Gipson Debbie, Kidd Jason M, |
| Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study. BMC medicine 2023 1 21 (1): 11. Shi Yuankai, Zhou Jianying, Zhao Yanqiu, Zhu Bo, Zhang Liangming, Li Xingya, Fang Jian, Shi Jianhua, Zhuang Zhixiang, Yang Sheng, Wang Donglin, Yu Huiqing, Zhang Longzhen, Zheng Rongsheng, Greco Michael, Wang Tingti |
| Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution. Heliyon 2023 1 8 (12): e12374. Yang Hainan, Wen Lei, Zhao Chao, Chen Jianing, Zhou Zhaoming, Zhou Cheng, Cai Linbo, Zhou Caic |
| Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients. Clinical lung cancer 2023 1 . Chen Minjiang, Xu Yan, Zhao Jing, Liu Xiaoyan, Liu Xiangning, Zhang Dongming, Shi Yuequan, Zhang Li, Zhong Wei, Wang Mengzh |
| Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report. Medicine 2023 1 101 (49): e31875. Zhao Nan, Xin Hua, Qin Changjuan, Li Zhiqi, Sun Hongb |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 29, 2023
- Content source: